These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26318434)

  • 1. The role of P2X7 receptors in tissue fibrosis: a brief review.
    Gentile D; Natale M; Lazzerini PE; Capecchi PL; Laghi-Pasini F
    Purinergic Signal; 2015 Dec; 11(4):435-40. PubMed ID: 26318434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential.
    Baudelet D; Lipka E; Millet R; Ghinet A
    Curr Med Chem; 2015; 22(6):713-29. PubMed ID: 25515510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of purinergic receptors and NOD-like receptor-family protein 3-inflammasome pathway in the adenosine triphosphate-induced cytokine release from macrophages.
    Gicquel T; Victoni T; Fautrel A; Robert S; Gleonnec F; Guezingar M; Couillin I; Catros V; Boichot E; Lagente V
    Clin Exp Pharmacol Physiol; 2014 Apr; 41(4):279-86. PubMed ID: 24472059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P2X7 Receptor as a Therapeutic Target.
    De Marchi E; Orioli E; Dal Ben D; Adinolfi E
    Adv Protein Chem Struct Biol; 2016; 104():39-79. PubMed ID: 27038372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of P2X7 receptor on inflammatory diseases and its mechanism].
    Xu H; Liang SD
    Sheng Li Xue Bao; 2013 Apr; 65(2):244-52. PubMed ID: 23598883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advance in the research on P2X7 and inflammatory respiratory diseases].
    Cao SH; Yuan SP; Hou Q
    Yao Xue Xue Bao; 2013 Aug; 48(8):1183-8. PubMed ID: 24187823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2X7 receptor in cardiovascular disease: The heart side.
    Guerra Martinez C
    Clin Exp Pharmacol Physiol; 2019 Jun; 46(6):513-526. PubMed ID: 30834550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adipocyte P2X7 receptors expression: a role in modulating inflammatory response in subjects with metabolic syndrome?
    Madec S; Rossi C; Chiarugi M; Santini E; Salvati A; Ferrannini E; Solini A
    Atherosclerosis; 2011 Dec; 219(2):552-8. PubMed ID: 21978920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7.
    Hattori F; Ohshima Y; Seki S; Tsukimoto M; Sato M; Takenouchi T; Suzuki A; Takai E; Kitani H; Harada H; Kojima S
    Eur J Pharmacol; 2012 Nov; 695(1-3):20-6. PubMed ID: 22981895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purinergic receptors: new targets for the treatment of gout and fibrosis.
    Gicquel T; Le Daré B; Boichot E; Lagente V
    Fundam Clin Pharmacol; 2017 Apr; 31(2):136-146. PubMed ID: 27885718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P2X7 receptor antagonists: a patent review (2010-2015).
    Park JH; Kim YC
    Expert Opin Ther Pat; 2017 Mar; 27(3):257-267. PubMed ID: 27724045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease.
    Bartlett R; Stokes L; Sluyter R
    Pharmacol Rev; 2014 Jul; 66(3):638-75. PubMed ID: 24928329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of P2X7 receptor in infectious inflammatory diseases and the influence of ectonucleotidases.
    Morandini AC; Savio LE; Coutinho-Silva R
    Biomed J; 2014; 37(4):169-77. PubMed ID: 25116711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of P2X7 antagonists with a focus on CNS indications.
    Rech JC; Bhattacharya A; Letavic MA; Savall BM
    Bioorg Med Chem Lett; 2016 Aug; 26(16):3838-45. PubMed ID: 27426304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The P2X7 purinergic receptor: An emerging therapeutic target in cardiovascular diseases.
    Chen Z; He L; Li L; Chen L
    Clin Chim Acta; 2018 Apr; 479():196-207. PubMed ID: 29366837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2X7 blockade attenuates mouse liver fibrosis.
    Huang C; Yu W; Cui H; Wang Y; Zhang L; Han F; Huang T
    Mol Med Rep; 2014 Jan; 9(1):57-62. PubMed ID: 24247209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2X7 receptor signaling in the pathogenesis of smoke-induced lung inflammation and emphysema.
    Lucattelli M; Cicko S; Müller T; Lommatzsch M; De Cunto G; Cardini S; Sundas W; Grimm M; Zeiser R; Dürk T; Zissel G; Sorichter S; Ferrari D; Di Virgilio F; Virchow JC; Lungarella G; Idzko M
    Am J Respir Cell Mol Biol; 2011 Mar; 44(3):423-9. PubMed ID: 20508069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states.
    Donnelly-Roberts DL; Jarvis MF
    Br J Pharmacol; 2007 Jul; 151(5):571-9. PubMed ID: 17471177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2X7 receptor antagonism in the treatment of cancers.
    Roger S; Pelegrin P
    Expert Opin Investig Drugs; 2011 Jul; 20(7):875-80. PubMed ID: 21619470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice.
    Engel T; Gomez-Villafuertes R; Tanaka K; Mesuret G; Sanz-Rodriguez A; Garcia-Huerta P; Miras-Portugal MT; Henshall DC; Diaz-Hernandez M
    FASEB J; 2012 Apr; 26(4):1616-28. PubMed ID: 22198387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.